Cassidy Bio

Company Overview

Snapshot

Founded in March 2024 by Rom Kshuk, Ayal Hendel, and Yaniv Shmueli, Cassidy Bio operates with 11–50 employees. The company has raised $8 million across one funding round from 5 investors. In August 2024, Cassidy Bio secured funding from investors including.

Business overview

Cassidy Bio is an AI-first biotechnology company focused on developing a programmable platform for gene editing. The company's core technology replaces traditional trial-and-error design processes with large-scale prediction, simulation, and in silico validation, powered by genomic foundation models trained on proprietary biological data. This platform is designed to connect multiple components, including guides, editing systems, delivery systems, and variant backgrounds, ranking designs by safety and efficacy. Cassidy Bio aims to enable a new generation of reliable gene editing therapies at scale, serving the pharmaceuticals and biotechnology sectors within the broader healthcare and life sciences market.

Strategic signal

In November 2025, Cassidy Bio's founders, who include veterans in CRISPR, AI, and biotech, highlighted their focus on improving the safety and specificity of therapy development. This signals a strategic emphasis on addressing critical challenges in gene editing, positioning the company to potentially deliver more effective and safer therapeutic solutions to the market.

Company Intelligence Q&A

When was Cassidy Bio founded and by whom?

Cassidy Bio was founded in March 2024 by Rom Kshuk, Ayal Hendel, and Yaniv Shmueli.

What is Cassidy Bio's primary focus?

Cassidy Bio is an AI-first biotechnology company building a programmable platform for gene editing, aiming to enable a new generation of reliable gene editing therapies at scale.

What was a key development for Cassidy Bio in August 2024?

In August 2024, Cassidy Bio secured funding from investors including.

What was highlighted by Cassidy Bio's founders in November 2025?

In November 2025, Cassidy Bio's founders emphasized their focus on improving the safety and specificity in therapy development, leveraging their expertise in CRISPR, AI, and biotech.

What is Cassidy Bio's total disclosed capital raised?

Cassidy Bio has raised $8 million across one funding round.